UA College of Pharmacy faculty member develops inhalers to treat lung diseases

February 22, 2016

TUCSON, Ariz. - Heidi M. Mansour, PhD, assistant professor in the University of Arizona College of Pharmacy, is working to develop advanced dry powder inhalers to treat and prevent pulmonary diseases.

Dr. Mansour investigates pulmonary states and diseases that have unmet medical needs, including lung transplants, lung cancer, chronic obstructive pulmonary disease, pulmonary fibrosis, bronchiolitis obliterans syndrome, cystic fibrosis, pulmonary infections and pulmonary hypertension. Her goal is to design treatments for these pulmonary conditions by researching and developing new drugs and by developing the delivery mechanisms for these drugs. Her specialty is dry powder inhalation aerosols -- that is, inhalers.

She recently published a paper in the journal Expert Opinion on Drug Delivery titled, "Dry Powder Inhalers in COPD, Lung Inflammation and Pulmonary Infections," detailing this research. The paper discusses currently available dry powder inhalers for inhalable powder drug formulations used in the treatment of COPD, asthma and pulmonary infections.

Delivering drugs to the lungs is the best way to treat many pulmonary diseases, Dr. Mansour said. However, unique challenges and complexities accompany this method of drug delivery.

"The lung is the organ of life that we're targeting, so there are added regulations and added safety limits that we have to work within," Dr. Mansour said. "You're restricted in the volume and mass you can deliver because you can't block the airways and suffocate the patient. There are added regulations for this class of products within the FDA."

To Dr. Mansour, these challenges are worth the reward of seeing a product help patients live better lives. Her goal for this research is to see these advanced dry powder inhalers end up on pharmacy shelves, remembering that the point of lab research is to have a positive therapeutic effect on people's health while meeting unmet medical needs.

"Our research program integrates fundamental principles of nanotechnology, solid-state particle engineering design, aerosol science, lung biophysics and biomedical drug delivery approaches to the development of aerosol medicine as high-performing multifunctional dry powder inhalers (DPIs) to treat complex lung conditions for precision pulmonary medicine," she said.

"Our team has been successfully designing and tailoring multifunctional DPIs -- novel formulations and inhaler devices -- for a number of complex pulmonary diseases that have historically been challenging to effectively treat. Our research lab is one of only a very few labs in the United States that conducts this cutting-edge scientific biomedical research in nanotechnology and multifunctional dry powder inhalers for targeted pulmonary delivery."
Dr. Mansour has faculty appointments in the University of Arizona BIO5 Institute, the UA Institute of the Environment and the UA Cancer Center. Her current and recent research funding has been from the National Institutes of Health, Cureveda, Buchi, the FDA, GlaxoSmithKline, Pfizer, DMV-Fonterra Excipients and InSys Therapeutics.

University of Arizona, College of Pharmacy

Related Drug Delivery Articles from Brightsurf:

Modelling microswimmers for drug delivery
An international group of theoretical physicists led by Abdallah Daddi-Moussa-Ider from Düsseldorf, Germany, has modelled the motion of microscopic, motile bodies - either powered micro-machines or living cells - in viscous liquid drops, using the Navier-Stokes equations.

Millimetre-precision drug delivery to the brain
Focused ultrasound waves help ETH researchers to deliver drugs to the brain with pinpoint accuracy, in other words only to where their effect is desired.

New smart drug delivery system may help treatment for neurological disorders
A Rutgers-led team has created a smart drug delivery system that reduces inflammation in damaged nervous tissues and may help treat spinal cord injuries and other neurological disorders.

Novel drug delivery particles use neurotransmitters as a 'passport' into the brain
Drug-carrying lipid nanoparticles were created that incorporate neurotranmitters to help them cross the blood-brain barrier in mice.

Advances in nanoparticles as anticancer drug delivery vector: Need of this century
This review article provides a summary of current advances in the use of nanoparticles (NPs) as anticancer drug-delivery vectors.

Microcapsules for targeted drug delivery to cancer cells
A team of scientists from Peter the Great St. Petersburg Polytechnic University together with their colleagues developed a method of targeted drug delivery to cancer cells.

Improving drug delivery for brain tumor treatment
Despite improvements in drug delivery mechanisms, treating brain tumors has remained challenging.

Nanoparticle orientation offers a way to enhance drug delivery
MIT engineers have shown that they can enhance the performance of drug-delivery nanoparticles by controlling an inherent trait of chemical structures, known as chirality -- the 'handedness' of the structure.

News about drug delivery
Nanocontainer for drugs can have their pitfalls: If they are too heavily loaded, they will only dissolve poorly.

Deflating beach balls and drug delivery
Gwennou Coupier and his colleagues at Grenoble Alps University, Grenoble, France have shown that macroscopic-level models of the properties of microscopic hollow spheres agree very well with theoretical predictions.

Read More: Drug Delivery News and Drug Delivery Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to